The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
The genetic tyrosinemias
Abstract
The genetic tyrosinemias are characterized by the accumulation of tyrosine in body fluids and tissues. The most severe form of tyrosinemia, Type I, is a devastating disorder of childhood that causes liver failure, painful neurologic crises, rickets, and hepatocarcinoma. This disorder is caused by a deficiency of fumarylacetoacetate hydrolase (FAH). If untreated, death typically occurs at less than 2 years of age, with some chronic forms allowing longer survival. It has a prevalence of about 1 in 100,000 newborns in the general population. Oculocutaneous tyrosinemia, Type II, is caused by a deficiency of tyrosine aminotransferase (TAT). It clinically presents with hyperkeratotic plaques on the hands and soles of the feet and photophobia due to deposition of tyrosine crystals within the cornea. Tyrosinemia Type III is an extremely rare disorder caused by a deficiency of 4‐hydroxyphenylpyruvic dioxygenase. It has been associated with ataxia and mild mental retardation. These disorders are diagnosed by observing elevated tyrosine by plasma amino acid chromatography and characteristic tyrosine metabolites by urine organic acid analysis. In tyrosinemia Type I, methionine is also elevated, reflecting impaired hepatocellular function. Urine organic acids show elevated p‐hydroxy‐phenyl organic acids in each type of tyrosinemia, and the pathognomic succinylacetone in tyrosinemia Type I. Diagnosis can be confirmed by enzyme or molecular studies in tyrosinemia Type I. Therapy consists of a diet low in phenylalanine and tyrosine for each of the tyrosinemias and 2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione (NTBC) for tyrosinemia Type I. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631
On the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447
Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)
Holme, E., & Lindstedt, S. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005410820201 · Cited by 264
Van Spronsen, F. J., Thomasse, Y., Smit, P. G. A., Leonard, J. V., Clayton, P. T., Fidler, V., Berger, R., & Heymans, H. S. A. (1994) · Hepatology · doi:10.1002/hep.1840200513 · Cited by 193
Self-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117509 · Cited by 168
Sassa, S., & Kappas, A. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110809 · Cited by 145 · cited 1×
“Succinylacetone is a potent inhibitor of two enzymes: 4-hydroxyphenylpyruvic acid dioxygenase (4-HPPD) and d-ALA dehydratase [Sassa and Kappas, 1983].”
BackgroundGrompe, M., St.-Louis, M., Demers, S. I., Al-Dhalimy, M., Leclerc, B., & Tanguay, R. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408113310603 · Cited by 135
Hall, M. G., Wilks, M. F., Provan, W. M., Eksborg, S., & Lumholtz, B. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01421.x · Cited by 110 · cited 1×
“Nitisinone has a half-life of approximately 54 hr [Hall et al., 2001], and at doses of approximately 1 mg/kg/ day, serum values are typically between 40 and 60 mM.”
BackgroundHereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect
Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116393 · Cited by 102 · cited 1×
“The children with the more chronic form of tyrosinemia-I, as manifest by chronic kidney disease, rickets, and growth failure, show a high incidence of allele reversion frommutant to normal in hepatic nodules [Kvittingen et al., 1993, 1994].”
BackgroundDemers, S. I., Russo, P., Lettre, F., & Tanguay, R. M. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00406-4 · Cited by 67
Cited by
Harnessing a High Cargo-Capacity Transposon for Genetic Applications in Vertebrates
Balciunas, D., Wangensteen, K. J., Wilber, A., Bell, J., Geurts, A., Sivasubbu, S., Wang, X., Hackett, P. B., Largaespada, D. A., McIvor, R. S., et al. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020169 · Cited by 335
Update in global trends and aetiology of hepatocellular carcinoma
Rawla, P., Sunkara, T., Muralidharan, P., & Raj, J. P. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.78941 · Cited by 332
Schlump, J.-U., Mayatepek, E., & Spiekerkoetter, U. (2010) · European Journal of Pediatrics · doi:10.1007/s00431-009-1074-1 · Cited by 13
Metadata
- Authors
- Scott, C. R.
- Venue
- American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Publisher
- Wiley
- Published
- 2006-04-06
- Volume
- 142C
- Issue
- 2
- Pages
- 121-126
- ISSN
- 1552-4868 (ISSN-L)
- 1552-4876
- OpenAlex
- W2139023170
- Cited by
- 186
- References
- 10
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The genetic tyrosinemias. https://app.cochat.ai/papers/10.1002/ajmg.c.30092
- The paper
- Scott, C. R. (2006). The genetic tyrosinemias. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. https://doi.org/10.1002/ajmg.c.30092
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.